| Exclusion Criteria: | 1) History of lymphoma or leukemia
2) Symptomatic or untreated central nervous system metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation, and corticosteroids
3) Subjects with head and neck cancer
4) Subjects with lung squamous cell tumors or with large central (located adjacent to or within the hilum or mediastinum) tumor lesions >/= 3 centimeters, regardless of histology
5) For the bevacizumab/AMG386 cohorts: Subjects with ovarian cancer
6) History of arterial or venous thrombosis or pulmonary embolism within 1 year before enrollment; history of bleeding diathesis
7) Myocardial infarction within 12 months before enrollment, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication
8) Chronic uncontrolled hypertension (diastolic > 85 mmHg; systolic > 145 mmHg)
9) History of pulmonary hemorrhage or gross hemoptysis within 6 months before enrollment
10) History of significant GI surgery or disease, which would impair absorption
11) Active infection within 2 weeks before enrollment
12) Subject known to have tested positive for HIV
13) Subject known to have chronic hepatitis (e.g., hepatitis B or hepatitis C)
14) Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to CTCAE grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria with the exception of alopecia
15) Any co-morbid medical condition that would increase the risk of toxicity
16) For subjects in cohorts involving AMG 706, sorafenib, or sunitinib (2, 4, 6, 7, 10 and 11 ) the following therapies and treatments are excluded: concurrent or prior rifampin phenobarbitol (within 2 weeks before enrollment); strong CYP 3A inhibitors such as ketoconazole, itraconazole, clairithromycin, erythromycin, nefazodone, grapefruit (i.e. whole fruit or fruit juice), or any HIV protease inhibitors (within 1 week prior to enrollment); immune modulators such as cyclosporine and tracrolimus (within 1 week prior to enrollment)
17) Continued from #17: St.John's Wort or any herbal therapy containing St.John's Wort (within 1 week prior to enrollment); Coumarin anticoagulants including warfarin, at doses greater than 2 mg/day. The concurrent use of low molecular weight heparin or low dose warfarin (i.e., </= 2 mg daily for prophylaxis against central venous catheter thrombosis is acceptable
18) Prior anti-tumor therapies: treatment with anti-cancer therapy within 30 days before study day 1 (including chemotherapy, retinoid, vaccine or tumor directed antibody therapy) except for treatment with bevacizumab within 42 days of study day 1, unless prior written approval is received from sponsor
19) For cohorts 1-4, prior treatment with bevacizumab, sorafenib, sutent or investigational agents known to directly inhibit the functions of VEGFR, angiopoeitins, or angiopoeitin receptors, unless prior written approval received from the sponsor
20) For cohorts 6-7, prior treatment with sorafenib, unless prior writeen approval is received from the sponsor.
21) For cohorts 10-11, prior treatment with sunitinib, unless prior written approval is received from the sponsor. For cohorts 6 and 7, 10 and 11, treatment with bevacizumab within 42 days before study day 1, unless prior written approval is received from the sponsor.
22) Known allergy to the excipients, or study drugs
23) History of allergic reactions to bacterially-produced proteins
24) Prior treatment with AMG 386
25) Subject has previously entered this study
26) Major surgery within 30 days before enrollment or recovering from prior surgery
27) Subject who is pregnant or nursing
28) Any disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures
29) Prior radiation therapy to the abdomen
30) Cardiovascular events within 1 year before enrollment, such as myocardial infarction, unstable/severe angina, coronary/peripheral artery bypass graft, unstable cardiac arrhythmia requiring medication, symptomatic congestive heart failure (New York Heart Association >class II), cerebrovascular accident or transient ischemic attack; LVEF </= 45% (for cohorts 10 and 11); Heart rate < 50 / min (for cohorts 10 and 11)
31) Prior anti-tumor therapies: Hormonal anti-tumor therapy within 30 days before enrollment. Does not include hormones for non-cancer related conditions (e.g., insulin for diabetes, RT) or the use of GnRH agonists for prostate cancer; therapeutic or palliative radiation therapy within 2 wks before enrollment (subjects must have resolution of any significant AEs from radiation therapy received prior to 2 wks before enrollment) |